Proposal seeks FDA center for rare diseases

An FDA Rare Disease Center of Excellence (COE) could bring greater consistency and efficiency to regulatory review for rare disease products, according to a proposal from Hyman, Phelps & McNamara's Frank Sasinowski and James Valentine.